Literature DB >> 30197148

Efficacy of vaccination with a Klebsiella pneumoniae siderophore receptor protein vaccine for reduction of Klebsiella mastitis in lactating cattle.

P J Gorden1, M D Kleinhenz2, J A Ydstie2, T A Brick2, L M Slinden3, M P Peterson3, D E Straub3, D T Burkhardt3.   

Abstract

Clinical mastitis caused by Klebsiella spp. is an emerging problem in the US dairy industry and results in a high degree of financial losses to dairy workers. This study was conducted as a randomized, blinded, and placebo-controlled efficacy study of a Klebsiella pneumoniae siderophore receptor protein (SRP) vaccine (Kleb-SRP), with a total of 569 cows and heifers enrolled. The study was designed to look at vaccine effect on Klebsiella mastitis; however, the SRP in Klebsiella are highly conserved across coliform bacteria, which means that the vaccine has potential for cross-protection against all coliforms. Cows were paired based on parity, days in milk at enrollment, and somatic cell count. Within pairs, individuals were randomized to receive either Kleb-SRP or a placebo formulation. Following vaccination, the incidence of Klebsiella spp. and total coliform mastitis from natural exposure were compared to determine the efficacy of the vaccine. When analyzing all cows, the reduction of mastitis risk was not significant, though milk production increased 0.31 kg/d and somatic cell counts were reduced by 20.1%. When administered before calving, the vaccine reduced the risk of Klebsiella and total coliform mastitis by 76.9 and 47.5% respectively; however, we observed no significant effect when administered after calving. The vaccine, when administered before calving, also increased milk production by an average of 1.74 kg/d and reduced somatic cell counts by 64.8%. When administered after calving, we noted a slight decrease in daily milk production (0.39 kg) but no significant effect on somatic cell counts. All cows in the study (including vaccinates and placebo) received multiple doses of a commercially available licensed Escherichia coli bacterin. It should be noted that this herd was chosen because of the high number of clinical Klebsiella clinical mastitis cases this herd experienced before the trial and the extreme environmental challenge that was present from bedding with dried manure solids. The data from this study demonstrate efficacy of the Kleb-SRP vaccine against Klebsiella mastitis alone and coliform mastitis in general (including all coliforms) when administered before the initiation of a lactation cycle.
Copyright © 2018 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Klebsiella spp.; bovine mastitis; siderophore receptors

Mesh:

Substances:

Year:  2018        PMID: 30197148     DOI: 10.3168/jds.2017-14267

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  9 in total

1.  Progress towards the development of Klebsiella vaccines.

Authors:  Myeongjin Choi; Sharon M Tennant; Raphael Simon; Alan S Cross
Journal:  Expert Rev Vaccines       Date:  2019-06-28       Impact factor: 5.217

Review 2.  Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies.

Authors:  Clement Opoku-Temeng; Natalia Malachowa; Scott D Kobayashi; Frank R DeLeo
Journal:  J Innate Immun       Date:  2021-10-08       Impact factor: 7.111

3.  Comparative Pathogenomics of Escherichia coli: Polyvalent Vaccine Target Identification through Virulome Analysis.

Authors:  J R Clark; A M Maresso
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

4.  Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From Pseudomonas aeruginosa Acute Murine Pneumonia.

Authors:  Emel Sen-Kilic; Catherine B Blackwood; Dylan T Boehm; William T Witt; Aaron C Malkowski; Justin R Bevere; Ting Y Wong; Jesse M Hall; Shelby D Bradford; Melinda E Varney; Fredrick Heath Damron; Mariette Barbier
Journal:  Front Immunol       Date:  2019-10-23       Impact factor: 7.561

Review 5.  Application of TonB-Dependent Transporters in Vaccine Development of Gram-Negative Bacteria.

Authors:  Jia Wang; Kun Xiong; Qu Pan; Weifeng He; Yanguang Cong
Journal:  Front Cell Infect Microbiol       Date:  2021-01-27       Impact factor: 5.293

Review 6.  Progress towards the Elusive Mastitis Vaccines.

Authors:  Pascal Rainard; Florence B Gilbert; Rodrigo P Martins; Pierre Germon; Gilles Foucras
Journal:  Vaccines (Basel)       Date:  2022-02-15

7.  High Affinity Iron Acquisition Systems Facilitate but Are Not Essential for Colonization of Chickens by Salmonella Enteritidis.

Authors:  Dinesh H Wellawa; Po-King S Lam; Aaron P White; Susantha Gomis; Brenda Allan; Wolfgang Köster
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

8.  2018 Survey of antimicrobial drug use and stewardship practices in adult cows on California dairies: post-Senate Bill 27.

Authors:  Pius S Ekong; Essam M Abdelfattah; Emmanuel Okello; Deniece R Williams; Terry W Lehenbauer; Betsy M Karle; Joan D Rowe; Edith S Marshall; Sharif S Aly
Journal:  PeerJ       Date:  2021-07-13       Impact factor: 2.984

9.  Immunogenic characteristics of the outer membrane phosphoporin as a vaccine candidate against Klebsiella pneumoniae.

Authors:  Gaowei Hu; Xue Chen; Wenhui Chu; Zhe Ma; Yingjie Miao; Xi Luo; Yongqian Fu
Journal:  Vet Res       Date:  2022-01-21       Impact factor: 3.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.